Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with CTEPH either inoperable or with persistent or recurrent PH after surgery.~Exclusion Criteria:~* All types of pulmonary hypertension except subtypes 4.1 and 4.2 of the Venice Clinical Classification of Pulmonary Hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Riociguat (Adempas, BAY63-2521)_individual dose titration (Type: EXPERIMENTAL): Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Participants received Placebo orally as a film-coated tablet three times daily (tid) for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).